ZA200504387B - Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents. - Google Patents
Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents. Download PDFInfo
- Publication number
- ZA200504387B ZA200504387B ZA200504387A ZA200504387A ZA200504387B ZA 200504387 B ZA200504387 B ZA 200504387B ZA 200504387 A ZA200504387 A ZA 200504387A ZA 200504387 A ZA200504387 A ZA 200504387A ZA 200504387 B ZA200504387 B ZA 200504387B
- Authority
- ZA
- South Africa
- Prior art keywords
- carboxylic acid
- thiophene
- alkyl
- aryl
- cycloalkyl
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title description 4
- 230000002519 immonomodulatory effect Effects 0.000 title description 4
- 230000001028 anti-proliverative effect Effects 0.000 title description 3
- 150000001491 aromatic compounds Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- -1 -SH Chemical group 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 30
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 125000001188 haloalkyl group Chemical group 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 claims description 16
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 claims description 16
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000004122 cyclic group Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 11
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 125000003367 polycyclic group Chemical group 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- CMSCIKGPPSZJCR-UHFFFAOYSA-N 4-[(4-naphthalen-2-yl-1,3-thiazol-2-yl)carbamoyl]furan-3-carboxylic acid Chemical compound OC(=O)C1=COC=C1C(=O)NC1=NC(C=2C=C3C=CC=CC3=CC=2)=CS1 CMSCIKGPPSZJCR-UHFFFAOYSA-N 0.000 claims description 2
- IGZXVCCGRAIYSA-UHFFFAOYSA-N 5-[(4-naphthalen-2-yl-1,3-thiazol-2-yl)carbamoyl]-2h-triazole-4-carboxylic acid Chemical compound OC(=O)C1=NNN=C1C(=O)NC1=NC(C=2C=C3C=CC=CC3=CC=2)=CS1 IGZXVCCGRAIYSA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- QUZTWSMTEVXSPF-UHFFFAOYSA-N 2-(tert-butylcarbamoyl)thiophene-3-carboxylic acid Chemical compound CC(C)(C)NC(=O)C=1SC=CC=1C(O)=O QUZTWSMTEVXSPF-UHFFFAOYSA-N 0.000 claims 3
- YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical compound OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 claims 3
- NZOLKIUOTPQVOQ-UHFFFAOYSA-N 3-(propan-2-ylcarbamoyl)thiophene-2-carboxylic acid Chemical compound CC(C)NC(=O)C=1C=CSC=1C(O)=O NZOLKIUOTPQVOQ-UHFFFAOYSA-N 0.000 claims 2
- IHCCAYCGZOLTEU-UHFFFAOYSA-N 3-furoic acid Chemical compound OC(=O)C=1C=COC=1 IHCCAYCGZOLTEU-UHFFFAOYSA-N 0.000 claims 2
- IACYWQZBPYYSMB-UHFFFAOYSA-N 2-(dimethylcarbamoyl)thiophene-3-carboxylic acid Chemical compound CN(C)C(=O)C=1SC=CC=1C(O)=O IACYWQZBPYYSMB-UHFFFAOYSA-N 0.000 claims 1
- LNOOSIAAAWRNAD-UHFFFAOYSA-N 2-(ethylcarbamoyl)thiophene-3-carboxylic acid Chemical compound CCNC(=O)C=1SC=CC=1C(O)=O LNOOSIAAAWRNAD-UHFFFAOYSA-N 0.000 claims 1
- HGZGDMAYBFUUFW-UHFFFAOYSA-N 2-(phenylcarbamoyl)furan-3-carboxylic acid Chemical compound C1=COC(C(=O)NC=2C=CC=CC=2)=C1C(=O)O HGZGDMAYBFUUFW-UHFFFAOYSA-N 0.000 claims 1
- CYYDCXXRPAYVGR-UHFFFAOYSA-N 2-(phenylcarbamoyl)thiophene-3-carboxylic acid Chemical compound C1=CSC(C(=O)NC=2C=CC=CC=2)=C1C(=O)O CYYDCXXRPAYVGR-UHFFFAOYSA-N 0.000 claims 1
- YTKRFDCFPYKBHO-UHFFFAOYSA-N 2-(propan-2-ylcarbamoyl)furan-3-carboxylic acid Chemical compound CC(C)NC(=O)C=1OC=CC=1C(O)=O YTKRFDCFPYKBHO-UHFFFAOYSA-N 0.000 claims 1
- GWZMIBAGTLDOFN-UHFFFAOYSA-N 2-(tert-butylcarbamoyl)furan-3-carboxylic acid Chemical compound CC(C)(C)NC(=O)C=1OC=CC=1C(O)=O GWZMIBAGTLDOFN-UHFFFAOYSA-N 0.000 claims 1
- IAVZZEMLMOEQOK-UHFFFAOYSA-N 2-[(2,5-dibromothiophen-3-yl)carbamoyl]thiophene-3-carboxylic acid Chemical compound C1=CSC(C(=O)NC2=C(SC(Br)=C2)Br)=C1C(=O)O IAVZZEMLMOEQOK-UHFFFAOYSA-N 0.000 claims 1
- QFHMYSHYSGYAFC-UHFFFAOYSA-N 2-[(2,5-dichlorothiophen-3-yl)carbamoyl]thiophene-3-carboxylic acid Chemical compound C1=CSC(C(=O)NC2=C(SC(Cl)=C2)Cl)=C1C(=O)O QFHMYSHYSGYAFC-UHFFFAOYSA-N 0.000 claims 1
- PSASPXQXYYWSDW-UHFFFAOYSA-N 2-[(4-chlorophenyl)carbamoyl]thiophene-3-carboxylic acid Chemical compound C1=CSC(C(=O)NC=2C=CC(Cl)=CC=2)=C1C(=O)O PSASPXQXYYWSDW-UHFFFAOYSA-N 0.000 claims 1
- RAQNAMMQJITSHO-UHFFFAOYSA-N 2-[[3-(trifluoromethyl)phenyl]carbamoyl]thiophene-3-carboxylic acid Chemical compound C1=CSC(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1C(=O)O RAQNAMMQJITSHO-UHFFFAOYSA-N 0.000 claims 1
- ATAXWINYVVWLPZ-UHFFFAOYSA-N 2-[methyl(phenyl)carbamoyl]thiophene-3-carboxylic acid Chemical compound C=1C=CC=CC=1N(C)C(=O)C=1SC=CC=1C(O)=O ATAXWINYVVWLPZ-UHFFFAOYSA-N 0.000 claims 1
- GRFOHUBBUMAJMM-UHFFFAOYSA-N 3-(2-aminoquinolin-3-yl)-n-cyclohexyl-n-methylpropanamide Chemical compound C=1C2=CC=CC=C2N=C(N)C=1CCC(=O)N(C)C1CCCCC1 GRFOHUBBUMAJMM-UHFFFAOYSA-N 0.000 claims 1
- GHMNNOGAAQKJOJ-UHFFFAOYSA-N 3-(phenylcarbamoyl)thiophene-2-carboxylic acid Chemical compound S1C=CC(C(=O)NC=2C=CC=CC=2)=C1C(=O)O GHMNNOGAAQKJOJ-UHFFFAOYSA-N 0.000 claims 1
- LSUJLRQVWMDYLD-UHFFFAOYSA-N 3-(tert-butylcarbamoyl)thiophene-2-carboxylic acid Chemical compound CC(C)(C)NC(=O)C=1C=CSC=1C(O)=O LSUJLRQVWMDYLD-UHFFFAOYSA-N 0.000 claims 1
- PFSKFXIVPBLBJE-UHFFFAOYSA-N 3-[methyl(phenyl)carbamoyl]thiophene-2-carboxylic acid Chemical compound C=1C=CC=CC=1N(C)C(=O)C=1C=CSC=1C(O)=O PFSKFXIVPBLBJE-UHFFFAOYSA-N 0.000 claims 1
- RUNMORKVPCSMTK-UHFFFAOYSA-N 3-formylthiophene-2-carboxylic acid Chemical compound OC(=O)C=1SC=CC=1C=O RUNMORKVPCSMTK-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010061217 Infestation Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000233872 Pneumocystis carinii Species 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- OLYIHCXRYTVESD-UHFFFAOYSA-N methyl 2-[methyl(phenyl)carbamoyl]thiophene-3-carboxylate Chemical compound C1=CSC(C(=O)N(C)C=2C=CC=CC=2)=C1C(=O)OC OLYIHCXRYTVESD-UHFFFAOYSA-N 0.000 claims 1
- HNJDJDFZVGHLOY-UHFFFAOYSA-N methyl 3-[methyl(phenyl)carbamoyl]thiophene-2-carboxylate Chemical compound S1C=CC(C(=O)N(C)C=2C=CC=CC=2)=C1C(=O)OC HNJDJDFZVGHLOY-UHFFFAOYSA-N 0.000 claims 1
- JLKDJHPRTZFHOP-UHFFFAOYSA-N n-tert-butylfuran-2-carboxamide Chemical compound CC(C)(C)NC(=O)C1=CC=CO1 JLKDJHPRTZFHOP-UHFFFAOYSA-N 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229960000681 leflunomide Drugs 0.000 description 3
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940059756 arava Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- YTIVTFGABIZHHX-UHFFFAOYSA-N butynedioic acid Chemical class OC(=O)C#CC(O)=O YTIVTFGABIZHHX-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(II) bromide Substances [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 150000003556 thioamides Chemical class 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 description 1
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 1
- 125000004507 1,2,5-oxadiazol-3-yl group Chemical group O1N=C(C=N1)* 0.000 description 1
- 125000004508 1,2,5-oxadiazol-4-yl group Chemical group O1N=CC(=N1)* 0.000 description 1
- 125000004518 1,2,5-thiadiazol-3-yl group Chemical group S1N=C(C=N1)* 0.000 description 1
- 125000004519 1,2,5-thiadiazol-4-yl group Chemical group S1N=CC(=N1)* 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OEUSNWDYXDEXDR-UHFFFAOYSA-N 1h-pyrrole-2,3-dicarboxylic acid Chemical class OC(=O)C=1C=CNC=1C(O)=O OEUSNWDYXDEXDR-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- XEIVFUWZYMWLEP-UHFFFAOYSA-N 9h-thioxanthene 10,10-dioxide Chemical compound C1=CC=C2S(=O)(=O)C3=CC=CC=C3CC2=C1 XEIVFUWZYMWLEP-UHFFFAOYSA-N 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101100246662 Homo sapiens DHODH gene Proteins 0.000 description 1
- 101000957333 Homo sapiens Muscleblind-like protein 3 Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100038751 Muscleblind-like protein 3 Human genes 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- FSEUPUDHEBLWJY-UHFFFAOYSA-N diacetylmonoxime Chemical class CC(=O)C(C)=NO FSEUPUDHEBLWJY-UHFFFAOYSA-N 0.000 description 1
- JWLIWPUUZTZGLA-UHFFFAOYSA-N diethyl 4-acetyl-5-methylfuran-2,3-dicarboxylate Chemical compound CCOC(=O)C=1OC(C)=C(C(C)=O)C=1C(=O)OCC JWLIWPUUZTZGLA-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001793 isothiazol-3-yl group Chemical group [H]C1=C([H])C(*)=NS1 0.000 description 1
- 125000004500 isothiazol-4-yl group Chemical group S1N=CC(=C1)* 0.000 description 1
- 125000004501 isothiazol-5-yl group Chemical group S1N=CC=C1* 0.000 description 1
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007122 ortho-metalation reaction Methods 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10260800 | 2002-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200504387B true ZA200504387B (en) | 2006-02-22 |
Family
ID=32667540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200504387A ZA200504387B (en) | 2002-12-23 | 2005-05-30 | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents. |
Country Status (22)
Country | Link |
---|---|
EP (3) | EP1578741B1 (pt) |
JP (3) | JP2006511564A (pt) |
KR (1) | KR101107456B1 (pt) |
CN (3) | CN1732163B (pt) |
AT (2) | ATE450498T1 (pt) |
AU (2) | AU2003293914B2 (pt) |
BR (2) | BR0317731A (pt) |
CA (2) | CA2509138A1 (pt) |
CY (1) | CY1111851T1 (pt) |
DE (1) | DE60330391D1 (pt) |
DK (1) | DK1578741T3 (pt) |
ES (1) | ES2368735T3 (pt) |
IL (2) | IL169184A (pt) |
MX (2) | MXPA05006890A (pt) |
NO (2) | NO20052907L (pt) |
NZ (1) | NZ541382A (pt) |
PL (2) | PL377478A1 (pt) |
PT (1) | PT1578741E (pt) |
RU (2) | RU2367650C2 (pt) |
SI (1) | SI1578741T1 (pt) |
WO (1) | WO2004056797A1 (pt) |
ZA (1) | ZA200504387B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0921258A2 (pt) * | 2008-11-07 | 2018-10-23 | 4Sc Ag | terapia combinatória compreendendo inibidor de dhodh e metotrexato para o tratamento de doença autoimune |
TWI530286B (zh) * | 2009-05-04 | 2016-04-21 | 帕納特斯製藥格斯有限公司 | 作為抑制病毒化合物之抗發炎劑 |
US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
US20140031383A1 (en) | 2011-02-08 | 2014-01-30 | Dana-Farber Cancer Institute, Inc. | Methods for treatment of melanoma |
RU2485112C1 (ru) * | 2012-04-26 | 2013-06-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | 4-(4-бромфенил)-4-оксо-2-{[3-(этоксикарбонил)-4,5-диметилтиен-2-ил]амино}-2-бутеновая кислота, обладающая противовоспалительной и анальгетической активностью |
KR102265277B1 (ko) | 2014-04-11 | 2021-06-16 | 판옵테스 파르마 게스.엠.베.하. | 바이러스 억제 화합물로서의 항-염증제 |
US11730716B2 (en) | 2014-05-08 | 2023-08-22 | Kiora Pharmaceuticals Gmbh | Compounds for treating ophthalmic diseases and disorders |
MX2019007434A (es) | 2016-12-21 | 2019-08-16 | Biotheryx Inc | Derivados de tienopirrol para uso en seleccion como diana de proteinas, composiciones, metodos y usos de los mismos. |
WO2022167402A1 (en) | 2021-02-02 | 2022-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor |
BR112023020806A2 (pt) | 2021-04-09 | 2023-12-12 | Immunic Ag | Inibidores de dhodh deuterados |
WO2023118576A1 (en) | 2021-12-23 | 2023-06-29 | Immunic Ag | Dhodh inhibitors containing a carboxylic acid bioisostere |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL186239B (nl) | 1975-06-05 | Hoechst Ag | Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze. | |
AU1526483A (en) * | 1982-06-14 | 1983-12-22 | Nippon Kayaku Kabushiki Kaisha | N-substituted-3,4,5,6-tetrahydrophthalamic acids |
ZA839187B (en) * | 1982-12-10 | 1984-07-25 | Ciba Geigy Ag | Amide compounds |
GB8311519D0 (en) * | 1983-04-27 | 1983-06-02 | Fisons Plc | Nitrogen heterocycles |
GB8323293D0 (en) * | 1983-08-31 | 1983-10-05 | Zyma Sa | Substituted flavene and thioflavene derivatives |
DE3402026A1 (de) | 1984-01-21 | 1985-07-25 | Basf Ag, 6700 Ludwigshafen | Neue 2-aminothiophenderivate |
DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
DE3812225A1 (de) * | 1988-04-13 | 1989-10-26 | Basf Ag | Isoxazol(isothiazol)-5-carbonsaeureamide |
DE59009528D1 (de) * | 1989-09-22 | 1995-09-21 | Basf Ag | Carbonsäureamide. |
DE3932052A1 (de) * | 1989-09-26 | 1991-04-04 | Basf Ag | Oxazol- bzw. thiazolcarbonsaeureamide |
DE3933573A1 (de) * | 1989-10-07 | 1991-04-18 | Basf Ag | Carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
DE59106349D1 (de) * | 1990-06-23 | 1995-10-05 | Basf Ag | Dicarbonsäureimide als Herbizide. |
DE4023048A1 (de) * | 1990-07-20 | 1992-01-23 | Basf Ag | Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
DE4108181A1 (de) * | 1991-03-14 | 1992-09-17 | Basf Ag | Isoxazol- und isothiazol-5-carbonsaeureamide |
EP0633771A4 (en) * | 1992-04-02 | 1995-02-22 | Smithkline Beecham Corporation | Compounds. |
JP3055365B2 (ja) * | 1993-06-30 | 2000-06-26 | 東洋インキ製造株式会社 | 2,5−ジ(アリールアミノ)−3,6−ジヒドロテレフタル酸ジアルキルエステル類の製造法およびこれを中間体とするキナクリドン類の製造法 |
GB9320299D0 (en) | 1993-10-01 | 1993-11-17 | Roussel Lab Ltd | Isoxazole derivatives |
DE19547648A1 (de) | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
DE19610955A1 (de) | 1996-03-20 | 1997-09-25 | Hoechst Ag | Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid |
US6218427B1 (en) * | 1996-08-27 | 2001-04-17 | Shionogi & Co., Ltd. | Chromene-3-carboxylate derivatives |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
CA2275796A1 (en) * | 1996-12-23 | 1998-07-02 | Donald Joseph Phillip Pinto | Nitrogen containing heteroaromatics as factor xa inhibitors |
ATE236890T1 (de) * | 1996-12-23 | 2003-04-15 | Bristol Myers Squibb Pharma Co | Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer |
US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
ES2239806T3 (es) | 1997-06-19 | 2005-10-01 | Bristol-Myers Squibb Pharma Company | Inhibidores del factor xa con un grupo de especificidad neutro p1. |
US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
AU2108099A (en) | 1998-01-30 | 1999-08-16 | Procept, Inc. | Immunosuppressive agents |
GB9804343D0 (en) | 1998-02-27 | 1998-04-22 | Univ Cardiff | Chemical compounds |
WO2000026197A1 (en) * | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Novel inhibitors of impdh enzyme |
JP4706810B2 (ja) * | 1999-06-24 | 2011-06-22 | 日本農薬株式会社 | ピリジン環ジカルボン酸ジアミド誘導体及び農園芸用殺虫剤並びにその使用方法 |
KR20020016839A (ko) * | 1999-06-24 | 2002-03-06 | 무라타 도시카즈 | 복소환 디카르복실산 디아미드 유도체, 농원예용 살충제및 그것의 사용 방법 |
WO2001021160A2 (en) * | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
JP2003510352A (ja) | 1999-10-01 | 2003-03-18 | インスティチュート オブ モレキュラー アンド セル バイオロジー | ウイルス媒介性疾病の治療用化合物 |
EP1227084B1 (en) * | 1999-10-28 | 2005-12-14 | Trine Pharmaceuticals, Inc. | Drug discharge pump inhibitors |
WO2001032628A1 (en) * | 1999-11-03 | 2001-05-10 | Bristol-Myers Squibb Pharma Company | Cyano compounds as factor xa inhibitors |
US6599926B2 (en) * | 2000-06-23 | 2003-07-29 | Bristol-Myers Squibb Company | Heteroaryl-phenyl substituted factor Xa inhibitors |
RU2181270C1 (ru) | 2000-07-21 | 2002-04-20 | Общество с ограниченной ответственностью "Медицинское предприятие "ХИТ плюс" | Способ повреждения термонетолерантных патологических биоструктур организма теплокровных |
JP2002128768A (ja) * | 2000-10-26 | 2002-05-09 | Dai Ichi Seiyaku Co Ltd | 薬剤排出ポンプ阻害作用を有する化合物 |
JP2002322054A (ja) * | 2001-04-26 | 2002-11-08 | Dai Ichi Seiyaku Co Ltd | 薬剤排出ポンプ阻害薬 |
AP1753A (en) * | 2001-06-11 | 2007-07-18 | Shire Biochem Inc | Thiophene derivatives as antiviral agents for flavvivirus infection |
WO2003006424A1 (en) * | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
DE10133665A1 (de) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
GB0219896D0 (en) * | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
JP4093023B2 (ja) * | 2002-11-15 | 2008-05-28 | コニカミノルタビジネステクノロジーズ株式会社 | 非磁性一成分現像用トナーおよび画像形成方法 |
-
2003
- 2003-12-17 CA CA002509138A patent/CA2509138A1/en not_active Abandoned
- 2003-12-17 CN CN2003801073546A patent/CN1732163B/zh not_active Expired - Fee Related
- 2003-12-17 CN CNA2006101397112A patent/CN1939896A/zh active Pending
- 2003-12-17 CN CNA2003801073550A patent/CN1732147A/zh active Pending
- 2003-12-17 MX MXPA05006890A patent/MXPA05006890A/es active IP Right Grant
- 2003-12-17 BR BR0317731-9A patent/BR0317731A/pt not_active IP Right Cessation
- 2003-12-17 PT PT03789317T patent/PT1578741E/pt unknown
- 2003-12-17 JP JP2004561332A patent/JP2006511564A/ja active Pending
- 2003-12-17 SI SI200332049T patent/SI1578741T1/sl unknown
- 2003-12-17 EP EP03789317A patent/EP1578741B1/en not_active Expired - Lifetime
- 2003-12-17 PL PL377478A patent/PL377478A1/pl not_active Application Discontinuation
- 2003-12-17 JP JP2004561331A patent/JP2006514023A/ja active Pending
- 2003-12-17 AT AT03799487T patent/ATE450498T1/de not_active IP Right Cessation
- 2003-12-17 NZ NZ541382A patent/NZ541382A/en not_active IP Right Cessation
- 2003-12-17 BR BR0317687-8A patent/BR0317687A/pt not_active Application Discontinuation
- 2003-12-17 KR KR1020057011710A patent/KR101107456B1/ko active IP Right Grant
- 2003-12-17 PL PL377467A patent/PL209303B1/pl unknown
- 2003-12-17 EP EP10185827A patent/EP2283898A1/en not_active Withdrawn
- 2003-12-17 DK DK03789317.9T patent/DK1578741T3/da active
- 2003-12-17 RU RU2005123402/04A patent/RU2367650C2/ru not_active IP Right Cessation
- 2003-12-17 EP EP03799487A patent/EP1581477B1/en not_active Expired - Lifetime
- 2003-12-17 RU RU2005123401/04A patent/RU2386625C2/ru active
- 2003-12-17 MX MXPA05006889A patent/MXPA05006889A/es active IP Right Grant
- 2003-12-17 AU AU2003293914A patent/AU2003293914B2/en not_active Ceased
- 2003-12-17 AT AT03789317T patent/ATE516284T1/de active
- 2003-12-17 WO PCT/EP2003/014433 patent/WO2004056797A1/en active Application Filing
- 2003-12-17 ES ES03789317T patent/ES2368735T3/es not_active Expired - Lifetime
- 2003-12-17 AU AU2003299316A patent/AU2003299316A1/en not_active Abandoned
- 2003-12-17 CA CA2509139A patent/CA2509139C/en not_active Expired - Lifetime
- 2003-12-17 DE DE60330391T patent/DE60330391D1/de not_active Expired - Lifetime
-
2005
- 2005-05-30 ZA ZA200504387A patent/ZA200504387B/en unknown
- 2005-06-15 NO NO20052907A patent/NO20052907L/no not_active Application Discontinuation
- 2005-06-15 IL IL169184A patent/IL169184A/en active IP Right Grant
- 2005-06-15 NO NO20052908A patent/NO335748B1/no not_active IP Right Cessation
- 2005-06-17 IL IL169257A patent/IL169257A/en not_active IP Right Cessation
-
2010
- 2010-06-03 JP JP2010127770A patent/JP5300789B2/ja not_active Expired - Fee Related
-
2011
- 2011-09-20 CY CY20111100906T patent/CY1111851T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7365094B2 (en) | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | |
ZA200504387B (en) | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents. | |
US7071355B2 (en) | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | |
CA2452491C (en) | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | |
AU2002325315A1 (en) | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | |
CZ124099A3 (cs) | Derivát amidu aminothiofenkarboxylové kyseliny, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje | |
KR20110008170A (ko) | 아미도-티오펜 화합물 및 이의 용도 | |
CA2497632A1 (fr) | Nouveaux derives de thiophene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
US20150018411A1 (en) | Compounds as ppar beta/delta inhibitors for treating ppar beta/delta-mediated diseases | |
EP1541198A1 (en) | Cycloalkyl compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |